LONDON, April 17, 2025 /PRNewswire/ -- Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, today announces it has acquired the FDA-approved Abbreviated New Drug ...

According to DATAINTELO, the global Everolimus market was valued at $2.5 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.1%, reaching around $4.8 billion by 2032.

FORT LAUDERDALE - Sunshine Biopharma Inc. (NASDAQ:SBFM), a pharmaceutical company known for its work in oncology and antivirals, has announced the release of Everolimus, a generic equivalent of ...

Everolimus is a generic equivalent of the brand name Afinitor®. Everolimus is indicated for the treatment of (i) advanced renal cell carcinoma, (ii) breast cancer in post-menopausal women with ...